Fenwick & West and Goodwin Procter represented Royalty Pharma plc in the transaction, and Latham & Watkins and Mazanti-Andersen represented Ascendis Pharma A/S. Ascendis Pharma A/S...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP advised Royalty Pharma in connection with its development funding. Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary...
You must be a Standard 1 Year member to access this content.
Fenwick & West, Goodwin Procter and Maiwald represented Royalty Pharma in the transaction, Wilmer Cutler Pickering Hale and Dorr represented PTC Therapeutics. Royalty Pharma plc (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Latham & Watkins and Mazanti-Andersen acted as legal advisors to Ascendis on the transaction, while Goodwin Procter, Kromann Reumert and Fenwick & West acted as legal...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Royalty Pharma, and Orrick Herrington & Sutcliffe represented Ferring Pharmaceuticals in the deal. Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals announced...
You must be a Standard 1 Year member to access this content.
Jones Day advised Royalty Pharma on the deal. Royalty Pharma have acquired a $500m interest in PureTech’s royalty in Karuna Therapeutics’ KarXT, with $100m cash up...
You must be a Standard 1 Year member to access this content.
Fenwick and Goodwin represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry,...
You must be a Standard 1 Year member to access this content.
Fenwick represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry, announced the...
You must be a Standard 1 Year member to access this content.
Fenwick represents Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry, announced IP diligence...
You must be a Standard 1 Year member to access this content.
Goodwin advised Royalty Pharma plc on the deal. Royalty Pharma plc (Nasdaq: RPRX) announced its definitive agreement to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from...
You must be a Standard 1 Year member to access this content.
Skadden advised Theravance Biopharma, while Goodwin Procter advised Royalty Pharma on the deal. Willkie Farr & Gallagher advised Innoviva on the sale of its stake in...
You must be a Standard 1 Year member to access this content.
Fenwick & West advised Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry,...
You must be a Standard 1 Year member to access this content.
